Regulation News

Financial regulation news from the SEC, FINRA, and government agencies. Track policy changes, enforcement actions, and compliance updates affecting markets.

Shell Announces Auditor Switch, Kazakhstan Investment Pause Amid Ongoing Buybacks
Regulation James Calloway

Shell Announces Auditor Switch, Kazakhstan Investment Pause Amid Ongoing Buybacks

Shell has selected PwC as its new auditor starting in 2027 and will halt new investments in Kazakhstan due to legal disputes. The company continues its share repurchase program.

SHEL
IHC Issues Phishing Alert as Shares Hold Steady Near 400 Dirhams
Regulation James Calloway

IHC Issues Phishing Alert as Shares Hold Steady Near 400 Dirhams

International Holding Company warns investors of fraudulent emails using its branding, while its stock trades flat at 399.60 dirhams. UAE equities edged higher amid focus on geopolitics and oil.

FXI
RTX Dividend Maintained Amid Pentagon Scrutiny on Defense Contractor Payouts
Regulation James Calloway

RTX Dividend Maintained Amid Pentagon Scrutiny on Defense Contractor Payouts

RTX affirmed its quarterly dividend while defense contractors await a Pentagon list that could restrict shareholder returns. The company's Raytheon unit has been flagged for responsiveness concerns.

RTX LMT NOC GD LHX
Netflix Gains as DOJ Expands Warner Deal Scrutiny; Hastings Files Share Transfer
Regulation James Calloway

Netflix Gains as DOJ Expands Warner Deal Scrutiny; Hastings Files Share Transfer

Netflix shares closed 1.6% higher at $82.20 amid a deepening Justice Department antitrust review of its $82.7 billion Warner Bros Discovery acquisition. Director Reed Hastings reported transferring 241,944 shares via a family trust.

NFLX
FDA Crackdown on Compounded Weight-Loss Drugs Boosts Eli Lilly Shares
Regulation James Calloway

FDA Crackdown on Compounded Weight-Loss Drugs Boosts Eli Lilly Shares

Eli Lilly stock gained 3.7% after FDA signaled action against telehealth firm Hims & Hers over $49 compounded weight-loss alternatives. Regulatory uncertainty continues to impact obesity drug market valuations.

LLY